beta-Funaltrexamine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
beta-Funaltrexamine
Beta-Funaltrexamine.svg
Names
IUPAC name
Methyl (2E)-4-{[(5α,6β)-17-(cyclopropylmethyl)-3,14-dihydroxy-4,5-epoxymorphinan-6-yl]amino}-4-oxo-2-butenoate
Identifiers
3D model (JSmol)
Abbreviations β-FNA
ChEBI
ChEMBL
ChemSpider
KEGG
  • InChI=1S/C25H30N2O6/c1-32-20(30)7-6-19(29)26-16-8-9-25(31)18-12-15-4-5-17(28)22-21(15)24(25,23(16)33-22)10-11-27(18)13-14-2-3-14/h4-7,14,16,18,23,28,31H,2-3,8-13H2,1H3,(H,26,29)/b7-6+/t16-,18-,23+,24+,25-/m1/s1
    Key: PQKHESYTSKMWFP-WZJCLRDWSA-N
  • COC(=O)/C=C/C(=O)N[C@@H]1CC[C@]2([C@H]3Cc4ccc(c5c4[C@]2([C@H]1O5)CCN3CC6CC6)O)O
Properties
C25H30N2O6
Molar mass 454.523 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

beta-Funaltrexamine (β-funaltrexamine) is an antagonist at μ-opioid receptors used experimentally.[1] Chemically, it is an amide of methyl fumarate with a naltrexone derivative.

See also[edit]

References[edit]

  1. ^ Huang, Weijiao; Manglik, Aashish; Venkatakrishnan, A. J.; Laeremans, Toon; Feinberg, Evan N.; Sanborn, Adrian L.; Kato, Hideaki E.; Livingston, Kathryn E.; Thorsen, Thor S.; Kling, Ralf C.; Granier, Sébastien; Gmeiner, Peter; Husbands, Stephen M.; Traynor, John R.; Weis, William I.; Steyaert, Jan; Dror, Ron O.; Kobilka, Brian K. (2015). "Structural insights into µ-opioid receptor activation". Nature. 524 (7565): 315–321. doi:10.1038/nature14886. PMC 4639397. PMID 26245379.